EBMT 2022 | An update on the latest developments in the field of CAR-T therapy
Christian Chabannon, MD, PhD, Paoli-Calmettes Institute, Marseille, France, outlines the latest developments in chimeric antigen receptor T-cell (CAR-T) therapy. Prof. Chabannon first highlights advances in the production of a new generation of CAR-Ts, and talks on the recent approval of the BCMA-directed CAR-T ciltacabtagene autoleucel (cilta-cel) in multiple myeloma. Finally, Prof. Chabannon comments on the ongoing discussions on moving CD19-targeted CAR-Ts from third-line to second-line in lymphoma. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
Transcript (edited for clarity)
Beyond the fact that there are very active developments for new generations of CAR-Ts, I think what’s probably most striking in this edition of the EBMT Annual Meeting, is the integration of CAR-Ts in care for patients with multiple myeloma, although we still have limited real-world experience with this new category of products, but we do now have access to CAR-Ts that target BCMA, B-cell maturation antigen, and are approved for treatment of patients with advanced multiple myeloma...
Beyond the fact that there are very active developments for new generations of CAR-Ts, I think what’s probably most striking in this edition of the EBMT Annual Meeting, is the integration of CAR-Ts in care for patients with multiple myeloma, although we still have limited real-world experience with this new category of products, but we do now have access to CAR-Ts that target BCMA, B-cell maturation antigen, and are approved for treatment of patients with advanced multiple myeloma. And the second striking aspect is the discussion that goes around moving CD19 CAR-Ts up one line in relapsing lymphoma patients. The three randomized trials that are available, two with positive conclusions, and one with negative conclusions are being discussed at length. And I believe that what may come out of this situation is a better definition of patients whom in the future may benefit from receiving CAR-Ts in second line. It is important to stress that at this stage, there is no approval for the use of CAR-Ts in second line for patients with lymphoma, but it is reasonable to think that the situation may evolve in the near future.
Read more...
Disclosures
Honorarium from Bellicum Pharmaceuticals / BMS Celgene / Kite Gilead / Novartis / Janssen Pharmaceuticals
